| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pathophysiology of Renal Disease and Progression |

* Human Craniofacial Genetics Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland; and
Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Address correspondence to: Dr. Thomas C. Hart, NIH-NIDCR, 10 Center Drive, Building 10, Room 5-2531, Bethesda, MD 20892-1432. Phone: 301-402-1706; Fax: 301-480-4455; E-mail: thart{at}mail.nih.gov
Received for publication May 4, 2005. Accepted for publication July 18, 2005.
As a consequence of uromodulin gene mutations, individuals develop precocious hyperuricemia, gout, and progressive renal failure. In vitro studies suggest that pathologic accumulation of uromodulin/Tamm-Horsfall glycoprotein (THP) occurs in the endoplasmic reticulum (ER), but the pathophysiology of renal damage is unclear. It was hypothesized that programmed cell death triggered by accumulation of misfolded THP in the ER causes progressive renal disease. Stably transfected human embryonic kidney 293 cells and immortalized thick ascending limb of Henles loop cells with wild-type and mutated uromodulin cDNA were evaluated to test this hypothesis. Immunocytochemistry, ELISA, and deglycosylation studies indicated that accumulation of mutant THP occurred in the ER. FACS analyses showed a significant increase in early apoptosis signal in human embryonic kidney 293 and thick ascending limb of Henles loop cells that were transfected with mutant uromodulin constructs. Colchicine and sodium 4-phenylbutyrate treatment increased secretion of THP from the ER to the cell membrane and into the culture media and significantly improved cell viability. These findings indicate that intracellular accumulation of THP facilitates apoptosis and that this may provide the pathologic mechanism responsible for the progressive renal damage associated with uromodulin gene mutations. Colchicine and sodium 4-phenylbutyrate reverse these processes and could potentially be beneficial in ameliorating the progressive renal damage in uromodulin-associated kidney diseases.
This article has been cited by other articles:
![]() |
P. Jennings, S. Aydin, P. Kotanko, J. Lechner, K. Lhotta, S. Williams, R. V. Thakker, and W. Pfaller Membrane Targeting and Secretion of Mutant Uromodulin in Familial Juvenile Hyperuricemic Nephropathy J. Am. Soc. Nephrol., January 1, 2007; 18(1): 264 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Codina, J. Liu, A. J. Bleyer, R. B. Penn, and T. D. DuBose Jr. Phosphorylation of S955 at the Protein Kinase A Consensus Promotes Maturation of the {alpha} Subunit of the Colonic H+,K+-ATPase J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1833 - 1840. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673